Expanding the genetic landscape of platelet reactivity modifiers in hemophilia: a multi-center study
An SWG Grant-supported project initiated by the SWG on Thrombocytopenias and Platelet Function Disorders (TPFD)
Full project title
Expanding the genetic landscape of platelet reactivity modifiers in hemophilia: a multi-center study (SWG on Thrombocytopenias and Platelet Function Disorders (TPFD))
Project Lead
Project background and aims
Hemophilia is traditionally classified according to the residual activity of coagulation factor VIII or IX. However, patients with the same degree of factor deficiency often show strikingly different bleeding tendencies: some experience frequent and severe hemorrhages, while others have a surprisingly mild clinical course. This discrepancy suggests that additional biological factors contribute to determining the bleeding phenotype. Our project aims to investigate one of these factors: the role of common genetic variants affecting platelet function.
Recent evidence from our preliminary studies indicates that naturally occurring genetic variants in platelet receptor genes can significantly modulate bleeding severity in hemophilia. Variants associated with reduced platelet activation appear to worsen bleeding, whereas variants linked to enhanced platelet reactivity may partially protect patients from hemorrhage. To validate and expand these findings, we propose a large international multicenter study involving 600–1000 patients with hemophilia from several European centers. We will comprehensively analyze platelet receptor variants and correlate them with detailed clinical data, including bleeding scores, annual bleeding rates, age at first bleeding, and joint health.
This grant is extremely important for us because it will allow the transition from promising pilot observations to a large-scale collaborative study with the statistical power and genetic coverage necessary to generate clinically meaningful results. The project has the potential to improve our understanding of why bleeding severity differs so markedly among hemophilia patients and could pave the way for personalized prognostic tools based on platelet genotyping.